{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:09:03Z","timestamp":1791918543925,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10147-020-01794-8","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T03:40:52Z","timestamp":1603251652000},"page":"111-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6583-7352","authenticated-orcid":false,"given":"Yoichiro","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Kuramochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Fukazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yoshimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the TAS CC3 Study Group.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"issue":"6","key":"1794_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1794_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ctrv.2014.02.006","volume":"40","author":"DL Nielsen","year":"2014","unstructured":"Nielsen DL et al (2014) A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan+\/\u2212 targeted therapy. Cancer Treat Rev 40(6):701\u2013715","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"1794_CR3","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T et al (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13(4):545\u2013549","journal-title":"Int J Mol Med"},{"issue":"1","key":"1794_CR4","first-page":"21","volume":"36","author":"J Chen","year":"2016","unstructured":"Chen J, Han M, Saif MW (2016) TAS-102 an emerging oral fluoropyrimidine. Anticancer Res 36(1):21\u201326","journal-title":"Anticancer Res"},{"issue":"9","key":"1794_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki Y et al (2017) TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol 18(9):1172\u20131181","journal-title":"Lancet Oncol"},{"issue":"19","key":"1794_CR6","first-page":"30827","volume":"S1470\u20132045","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer P et al (2020) TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol S1470\u20132045(19):30827\u201330837","journal-title":"Lancet Oncol"},{"issue":"1","key":"1794_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1186\/s12885-019-6475-6","volume":"19","author":"D Kotani","year":"2019","unstructured":"Kotani D et al (2019) Retrospective cohort study of trifluridine\/tipiracil (TAS-102) plus bevacizumab versus trifluridine\/tipiracil monotherapy for metastatic colorectal cancer. BMC cancer 19(1):1253\u20131253","journal-title":"BMC cancer"},{"issue":"3","key":"1794_CR8","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1634\/theoncologist.2019-0541","volume":"25","author":"H Fujii","year":"2020","unstructured":"Fujii H et al (2020) Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study. Oncologist 25(3):e469\u2013e476. https:\/\/doi.org\/10.1634\/theoncologist.2019-0541","journal-title":"Oncologist"},{"issue":"4","key":"1794_CR9","first-page":"390","volume":"11","author":"N Matsuhashi","year":"2019","unstructured":"Matsuhashi N et al (2019) Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: a single-center, retrospective study examining the prognostic value of the modified Glasgow prognostic score in salvage-line therapy of metastatic colorectal cancer. Mol Clin Oncol 11(4):390\u2013396","journal-title":"Mol Clin Oncol"},{"issue":"7","key":"1794_CR10","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.21873\/anticanres.12738","volume":"38","author":"Y Yoshida","year":"2018","unstructured":"Yoshida Y et al (2018) Biweekly administration of TAS-102 for neutropenia prevention in patients with colorectal cancer. Anticancer Res 38(7):4367\u20134373","journal-title":"Anticancer Res"},{"issue":"8","key":"1794_CR11","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol 27(8):1386\u20131422","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"20","key":"1794_CR12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909\u20131919","journal-title":"N Engl J Med"},{"issue":"4","key":"1794_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu J et al (2018) Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol 36(4):350\u2013358. https:\/\/doi.org\/10.1200\/JCO.2017.74.3245","journal-title":"J Clin Oncol"},{"issue":"9863","key":"1794_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312","journal-title":"Lancet"},{"issue":"8","key":"1794_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1758834017714997","volume":"9","author":"JM Loree","year":"2017","unstructured":"Loree JM, Kopetz S (2017) Recent developments in the treatment of metastatic colorectal cancer. Therap Adv Med Oncol 9(8):551\u2013564","journal-title":"Therap Adv Med Oncol"},{"issue":"7","key":"1794_CR16","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/cncr.29893","volume":"122","author":"M Takeda","year":"2016","unstructured":"Takeda M et al (2016) Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan oncology group 5910L): an open-label, randomized, phase 2 trial. Cancer 122(7):1050\u20131059","journal-title":"Cancer"},{"key":"1794_CR17","first-page":"3","volume":"7","author":"T Shoji","year":"2019","unstructured":"Shoji T et al (2019) A New therapeutic strategy for recurrent ovarian cancer-bevacizumab beyond progressive disease. Healthcare (Basel) 7:3","journal-title":"Healthcare (Basel)"},{"issue":"8","key":"1794_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/jnci\/djx288","volume":"110","author":"MJ Overman","year":"2018","unstructured":"Overman MJ et al (2018) The addition of bevacizumab to oxaliplatin-based chemotherapy: impact upon hepatic sinusoidal injury and thrombocytopenia. J Natl Cancer Inst 110(8):888\u2013894","journal-title":"J Natl Cancer Inst"},{"issue":"33","key":"1794_CR19","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","volume":"26","author":"A Grothey","year":"2008","unstructured":"Grothey A et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26(33):5326\u20135334","journal-title":"J Clin Oncol"},{"issue":"1","key":"1794_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14(1):29\u201337","journal-title":"Lancet Oncol"},{"issue":"7","key":"1794_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.3633","volume":"23","author":"A Grothey","year":"2014","unstructured":"Grothey A et al (2014) Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf 23(7):726\u2013734","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1794_CR22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tranon.2018.01.017","volume":"11","author":"S Becherirat","year":"2018","unstructured":"Becherirat S et al (2018) Discontinuous schedule of bevacizumab in colorectal cancer induces accelerated tumor growth and phenotypic changes. Trans Oncol 11(2):406\u2013415","journal-title":"Trans Oncol"},{"issue":"3","key":"1794_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.23922\/jarc.2018-043","volume":"3","author":"Y Yoshida","year":"2019","unstructured":"Yoshida Y et al (2019) A trial protocol of biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced\/recurrent colorectal cancer: a phase II multicenter clinical trial (The TAS-CC4 study). J Anus Rect Colon 3(3):136\u2013141","journal-title":"J Anus Rect Colon"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01794-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01794-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01794-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:03:57Z","timestamp":1634774637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01794-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1794"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01794-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"assertion":[{"value":"27 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Keiichiro Ishibashi has received research funding from Taiho and Chugai. Hideyuki Ishida has received research funding from Taiho and Chugai. Suguru Hasegawa has received research funding from Taiho and Takeda. The other authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}